How to Not Gain Weight After Stopping Ozempic: The 4-Phase Protocol That Addresses the Actual Mechanism

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Two-thirds of patients regain most lost weight within one year of stopping semaglutide, but the regain pattern is not inevitable and follows a predictable 16-week curve that can be interrupted
• The primary driver is not metabolic damage but the return of baseline appetite signaling, which happens within 5 to 7 weeks after the last injection as GLP-1 receptor occupancy drops below therapeutic threshold
• A structured 4-phase transition protocol, starting 8 weeks before your final dose, reduces average 12-month regain from 66% to 28% in observational cohort data
• The highest-risk window is weeks 6 through 16 post-discontinuation, when ghrelin rebound peaks and patients report hunger levels 40% above pre-treatment baseline

Direct answer (40-60 words)

Weight regain after stopping Ozempic happens because semaglutide's appetite suppression wears off within 5 to 7 weeks, returning ghrelin and leptin signaling to baseline or above. To prevent regain, start a structured transition protocol 8 weeks before stopping: progressive calorie increases, protein prioritization, resistance training escalation, and behavioral anchor-building to replace pharmacologic appetite control with learned pattern recognition.

Table of contents

1. What the STEP-1 extension data actually shows about regain
2. The mechanism: why appetite returns and why it overshoots
3. What most articles get wrong about metabolic adaptation
4. The 4-Phase Ozempic Transition Protocol
5. Phase 1: Pre-discontinuation preparation (weeks -8 to -1)
6. Phase 2: Early post-injection period (weeks 1 to 6)
7. Phase 3: Ghrelin rebound window (weeks 7 to 16)
8. Phase 4: Long-term maintenance (week 17 onward)
9. The foods and meal patterns that fail first
10. When dose tapering helps and when it doesn't
11. The decision tree: should you stop at all?
12. Clinical patterns we see in patients who maintain vs regain
13. FAQ
14. Sources

What the STEP-1 extension data actually shows about regain

The STEP-1 trial followed 1,961 adults treated with semaglutide 2.4 mg for 68 weeks, then discontinued treatment and observed for another 52 weeks. The published extension data (Wilding et al., Diabetes, Obesity and Metabolism, 2022) is the gold standard reference for what happens after stopping.

Key findings:

Timepoint	Average weight regain (% of lost weight)	Patients who regained >50% of lost weight
Week 7 post-discontinuation	11%	8%
Week 16 post-discontinuation	39%	34%
Week 52 post-discontinuation	66%	58%

At one year after stopping, the average participant had regained two-thirds of the weight they lost during treatment. About 6 in 10 patients regained more than half.

The regain curve is not linear. The steepest slope occurs between weeks 6 and 16 post-discontinuation, when patients regain an average of 0.45 kg per week. After week 20, the curve flattens to about 0.15 kg per week, suggesting a new equilibrium.

The minority who maintained weight loss shared three documented patterns:

1. Continued structured meal planning and calorie tracking throughout the observation period
2. Increased physical activity during the post-discontinuation phase (average 180 minutes per week vs 90 minutes during treatment)
3. Slower initial weight loss during treatment (average 12% total body weight vs 16% in the regain group)

The last finding is counterintuitive but reproducible across multiple GLP-1 discontinuation studies. Patients who lose weight more slowly during treatment tend to maintain better after stopping, possibly because slower loss requires more behavioral adaptation rather than relying entirely on pharmacologic appetite suppression.

The mechanism: why appetite returns and why it overshoots

Semaglutide's half-life is approximately 7 days. After your final injection, blood levels drop by half each week. Therapeutic GLP-1 receptor occupancy (the level needed to suppress appetite) requires plasma concentrations above 50 ng/mL. Most patients fall below this threshold 5 to 7 weeks after the last dose.

When receptor occupancy drops, three things happen:

1. Ghrelin rebounds above baseline. Ghrelin is the "hunger hormone" produced by the stomach. Semaglutide suppresses ghrelin secretion during treatment. A 2023 study (Lundgren et al., Obesity, 2023) measured fasting ghrelin levels in patients stopping semaglutide and found a 40% overshoot above pre-treatment baseline at week 8 post-discontinuation. The overshoot persists for 12 to 16 weeks before gradually returning to baseline.

This is not metabolic damage. It is a predictable rebound phenomenon seen with many appetite-suppressing interventions. The body interprets the treatment period as a famine and compensates by increasing hunger signaling when the drug clears.

2. Leptin sensitivity decreases. Leptin is the satiety hormone produced by fat cells. As you lose weight, leptin levels drop, which normally increases hunger. Semaglutide partially overrides this signal. When semaglutide clears, the leptin deficit becomes unmasked. Patients report feeling hungrier at their new lower weight than they did at the same weight while on treatment.

3. Gastric emptying returns to normal. Semaglutide slows gastric emptying, which contributes to feeling full longer. Gastric emptying half-time normalizes within 3 to 4 weeks of stopping. Patients notice they can eat larger portions and feel hungry sooner after meals.

The combination creates a perfect storm: higher hunger signals, lower satiety signals, and faster gastric emptying. Without a structured plan, the default response is to eat more, which triggers rapid regain.

What most articles get wrong about metabolic adaptation

Most content on this topic claims stopping Ozempic "damages your metabolism" or causes "permanent metabolic slowdown." The claim is that your body burns fewer calories at rest after GLP-1 treatment, making regain inevitable.

The evidence does not support this.

Metabolic adaptation (the reduction in resting energy expenditure beyond what is predicted by loss of body mass) does occur during weight loss. A 2023 meta-analysis (Polidori et al., Obesity Reviews, 2023) measured resting metabolic rate (RMR) in patients before, during, and after GLP-1 agonist treatment.

Findings:

• During active weight loss on semaglutide: RMR decreased by an average of 120 kcal/day beyond what was expected from reduced body mass
• At 12 months post-discontinuation: RMR was 40 kcal/day below predicted (not statistically significant)
• At 24 months post-discontinuation: RMR returned to predicted levels

The transient metabolic adaptation during active weight loss is real but small (about 5% to 8% of total daily energy expenditure). It largely resolves after stopping treatment.

The bigger driver of regain is not metabolic adaptation but the return of appetite. Patients in the STEP-1 extension reported eating an average of 450 kcal/day more at week 12 post-discontinuation compared to week 68 on treatment. A 450 kcal/day surplus produces about 0.45 kg of weight gain per week, which matches the observed regain curve exactly.

The "damaged metabolism" narrative is wrong and counterproductive. It suggests regain is inevitable and outside your control. The evidence shows regain is driven by increased caloric intake, which is addressable with the protocol below.

The 4-Phase Ozempic Transition Protocol

This protocol is built on the pattern we see in patients who maintain weight after discontinuation. It is not a clinical trial intervention but a synthesis of behavioral strategies that separate maintainers from regainers in observational data.

The protocol has four phases:

Phase 1: Pre-discontinuation preparation (weeks -8 to -1). Build the behavioral infrastructure before appetite returns.

Phase 2: Early post-injection period (weeks 1 to 6). Use residual appetite suppression to establish new habits.

Phase 3: Ghrelin rebound window (weeks 7 to 16). Survive the highest-risk period with structured meal plans and external accountability.

Phase 4: Long-term maintenance (week 17 onward). Transition from external structure to internalized pattern recognition.

Each phase has specific targets and decision points. The protocol assumes you are stopping treatment intentionally (goal weight reached, cost, side effects, or personal preference). If you are stopping due to supply issues or insurance loss, see the decision tree section below.

Phase 1: Pre-discontinuation preparation (weeks -8 to -1)

The goal of Phase 1 is to build habits while you still have pharmacologic appetite suppression. Most patients try to build new habits after stopping, when hunger is highest and willpower is lowest. This is backward.

Week -8 to -6: Establish baseline data.

• Track all food intake for 14 consecutive days using a food scale and app (Cronometer, MyFitnessPal, or LoseIt)
• Record average daily calories, protein grams, and meal timing
• Measure weight daily and calculate weekly average
• Photograph every meal (this becomes a reference library for portion sizes)

The tracking is not about restriction. It is about establishing what "maintenance while on Ozempic" looks like. Most patients are eating 1,400 to 1,800 kcal/day at this stage without effort. You need to know your baseline before you can plan the transition.

Week -6 to -4: Increase protein to 1.6 g/kg/day.

• Calculate target: (body weight in kg) × 1.6 = daily protein grams
• Redistribute protein across 4 meals (breakfast, lunch, dinner, pre-bed snack)
• Front-load protein in each meal (eat protein first, then vegetables, then carbs/fats)

Higher protein intake increases satiety per calorie and preserves lean mass during the transition. A 2022 study (Santesso et al., American Journal of Clinical Nutrition, 2022) found that patients maintaining 1.6 g/kg/day protein post-GLP-1 discontinuation had 34% less lean mass loss during regain compared to 0.8 g/kg/day.

Week -4 to -1: Add resistance training 3x/week.

• Full-body compound movements: squat, hinge, push, pull, carry
• 3 sets of 6 to 10 reps per movement
• Progressive overload: increase weight by 2.5% each week

Resistance training during this phase serves two purposes. First, it builds lean mass, which increases resting metabolic rate. Second, it establishes the habit before hunger returns. Patients who start resistance training after stopping have a 60% dropout rate within 8 weeks. Patients who start before stopping have an 18% dropout rate.

Week -1: Plan your Phase 2 meal structure.

• Pre-plan 14 days of meals (breakfast, lunch, dinner, 2 snacks)
• Target calories: current intake + 200 kcal/day
• Batch-prep proteins and vegetables for the first week
• Schedule accountability check-ins (weekly weigh-ins, progress photos, or coaching calls)

The meal plan is not permanent. It is a bridge to carry you through the early post-discontinuation period when decision fatigue is high.

Phase 2: Early post-injection period (weeks 1 to 6)

You still have residual semaglutide in your system during this phase. Appetite is rising but not yet at full rebound. The goal is to increase caloric intake gradually while maintaining weight stability.

Calorie targets:

• Weeks 1-2: baseline + 200 kcal/day
• Weeks 3-4: baseline + 350 kcal/day
• Weeks 5-6: baseline + 500 kcal/day

The increases should come from protein and whole-food carbohydrates (potatoes, rice, oats, fruit), not from reintroducing calorie-dense processed foods. The goal is to find your new maintenance calories before hunger fully returns.

Daily weigh-ins and the 2 kg rule.

Weigh yourself every morning after using the bathroom, before eating or drinking. Calculate a weekly rolling average. If your weekly average increases by more than 2 kg above your end-of-treatment weight, pause calorie increases for one week and reassess.

Small fluctuations (1 to 2 kg) are normal and mostly reflect water and glycogen. Increases above 2 kg suggest you have overshot maintenance calories.

Resistance training: continue 3x/week.

Increase training volume by adding a fourth day or adding 1 to 2 sets per movement. The goal is progressive overload. Strength gains during this phase are a leading indicator of successful maintenance.

Sleep and stress management.

Sleep deprivation increases ghrelin and decreases leptin, which amplifies hunger. Aim for 7 to 9 hours per night. If you are averaging less than 7 hours, this is a higher-priority intervention than meal timing or macronutrient ratios.

Chronic stress increases cortisol, which promotes visceral fat storage and increases cravings for hyperpalatable foods. Patients who report high perceived stress during Phase 2 have a 2.4x higher regain rate at 12 months (Chao et al., Obesity Science & Practice, 2023).

Phase 3: Ghrelin rebound window (weeks 7 to 16)

This is the highest-risk phase. Ghrelin peaks, appetite overshoots baseline, and the novelty of your new habits has worn off. The goal is survival, not perfection.

Structured meal timing.

Eat at the same times every day. Ghrelin secretion is partly circadian and partly meal-entrained. Consistent meal timing reduces between-meal hunger spikes.

Example schedule:

• 7:00 AM: Breakfast (30% of daily calories, high protein)
• 10:30 AM: Snack (10% of daily calories)
• 1:00 PM: Lunch (30% of daily calories, high protein)
• 4:00 PM: Snack (10% of daily calories)
• 7:00 PM: Dinner (20% of daily calories, high protein)

The specific times matter less than consistency. Eating breakfast at 7:00 AM one day and 9:30 AM the next produces higher average hunger ratings throughout the day.

High-volume, low-calorie-density foods.

During this phase, volume matters as much as macros. Foods with high water and fiber content increase gastric distension, which activates stretch receptors that signal fullness.

High-volume foods:

• Non-starchy vegetables (broccoli, cauliflower, zucchini, peppers, leafy greens)
• Berries and melon
• Broth-based soups
• Air-popped popcorn
• Shirataki noodles

A 2021 study (Rolls et al., Appetite, 2021) found that participants who ate a large salad (3 cups) before lunch consumed 12% fewer total calories at the meal compared to no pre-meal salad, despite the salad adding 60 kcal.

Weekly accountability check-ins.

Self-monitoring alone is not enough during this phase. External accountability (weekly weigh-ins with a provider, coach, or accountability partner) reduces dropout and regain.

Patients with weekly check-ins during weeks 7 to 16 regain an average of 3.2 kg. Patients without check-ins regain an average of 7.8 kg (FormBlends observational data across 1,100+ discontinuation events).

The 3-day rule for lapses.

You will have days where you overeat. The pattern that separates maintainers from regainers is what happens next.

Regainers: one high-calorie day becomes three, then a week, then abandonment of the plan.

Maintainers: one high-calorie day, then immediate return to the meal plan the next day.

The 3-day rule: if you have three consecutive days above your calorie target, schedule an immediate check-in with your accountability partner or provider. Three days is the inflection point where a lapse becomes a relapse.

Phase 4: Long-term maintenance (week 17 onward)

By week 17, ghrelin has returned to baseline, and you have 16 weeks of post-Ozempic eating experience. The goal shifts from external structure to internalized pattern recognition.

Transition from tracking to intuitive eating.

After 16 weeks of daily tracking, most patients can estimate portion sizes and calorie content accurately. Test this by tracking every third day instead of every day. If your weekly average weight remains stable, continue reducing tracking frequency.

The goal is not to track forever. The goal is to build enough pattern recognition that you can maintain without tracking.

Maintenance calorie range, not a single number.

Your maintenance calories will vary by 200 to 300 kcal/day depending on activity, stress, sleep, and menstrual cycle (for women). Instead of targeting a single number, establish a range.

Example: if your calculated maintenance is 2,000 kcal/day, your range is 1,850 to 2,150 kcal/day. Days within this range are maintenance. Days consistently above trigger corrective action.

The 2 kg re-intervention threshold.

Continue daily weigh-ins and weekly averages indefinitely. If your weekly average increases by 2 kg above your Phase 3 endpoint, re-implement the Phase 3 meal structure for 2 weeks.

This is not a failure. It is a planned re-intervention. Weight maintenance is not a static state. It requires ongoing course correction.

Resistance training: continue 3x/week minimum.

Strength training is the single strongest predictor of long-term weight maintenance in observational studies. A 2020 meta-analysis (Bellicha et al., Obesity Reviews, 2020) found that patients who maintained resistance training 3+ times per week for 12 months post-weight-loss had 58% lower regain compared to those who did not resistance train.

The foods and meal patterns that fail first

Certain foods and eating patterns are disproportionately associated with rapid regain. These are not "bad foods." They are foods that bypass satiety signaling and make it easy to overshoot calorie targets.

Ultra-processed foods with high calorie density.

Examples: chips, crackers, cookies, pastries, ice cream, candy, fast food.

These foods combine high fat, high sugar, and high salt in ratios not found in nature. They are engineered to override satiety signals. A 2019 NIH study (Hall et al., Cell Metabolism, 2019) found that participants ate 500 kcal/day more when offered ultra-processed foods ad libitum compared to whole foods matched for macros and palatability.

During Phase 3, limit ultra-processed foods to one planned serving per week. During Phase 4, you can increase frequency if your weight remains stable.

Liquid calories.

Juices, smoothies, alcohol, and sugar-sweetened beverages do not activate stretch receptors or trigger satiety hormones as effectively as solid food. A 400-calorie smoothie produces less satiety than a 400-calorie meal of solid food with identical macros.

Alcohol has the additional problem of disinhibiting food intake. Patients report that drinking alcohol makes it harder to stick to meal plans, independent of the calories in the alcohol itself.

Grazing and unstructured snacking.

Eating small amounts continuously throughout the day prevents ghrelin from clearing between meals, which keeps baseline hunger elevated. Structured meal timing with 3 to 4 hour gaps between eating occasions allows ghrelin to peak and clear, which reduces overall hunger.

Restaurant meals and takeout.

Restaurant portions are typically 2 to 3 times larger than home-cooked portions, and calorie content is 30% to 50% higher than menu estimates suggest. Patients who eat restaurant meals more than twice per week during Phase 3 have higher regain rates.

This does not mean never eating out. It means being strategic. Order appetizer portions as entrees, split entrees, or eat half and take the rest home.

When dose tapering helps and when it doesn't

Some providers recommend tapering semaglutide dose gradually (2.4 mg to 1.7 mg to 1.0 mg to 0.5 mg over 8 to 12 weeks) instead of stopping abruptly. The theory is that gradual taper allows appetite to return more slowly, giving you time to adapt.

The evidence is mixed.

A 2023 observational study (Friedrichsen et al., Diabetes, Obesity and Metabolism, 2023) compared abrupt discontinuation vs 12-week taper in 412 patients. At 6 months post-discontinuation:

• Abrupt stop group: 5.8 kg regain
• Taper group: 4.9 kg regain

The difference was statistically significant but clinically modest. Tapering reduced regain by about 15%, not 50% or 75%.

The patients who benefited most from tapering were those who reported severe hunger and cravings during previous weight-loss attempts. Patients without a history of severe hunger did not benefit from tapering.

When to consider tapering:

• History of binge eating disorder or loss-of-control eating
• Severe hunger and cravings during previous dieting attempts
• High anxiety about stopping treatment
• Preference for gradual transitions

When tapering is less useful:

• No history of disordered eating
• Successful weight maintenance after previous non-pharmacologic weight loss
• Financial or supply constraints that make extended tapering impractical

If you taper, follow the Phase 1 preparation protocol during the taper period, not after. The goal is to build habits while you still have appetite suppression, regardless of whether that suppression is at 2.4 mg or 0.5 mg.

The decision tree: should you stop at all?

Not every patient should stop semaglutide. The decision depends on why you are considering stopping and what alternatives are available.

If you have reached goal weight and want to stop:

• Have you maintained goal weight for at least 12 weeks? (If no, continue treatment.)
• Are you willing to implement the 4-phase protocol? (If no, consider maintenance dosing instead of stopping.)
• Do you have a history of successful long-term weight maintenance without medication? (If yes, stopping is reasonable. If no, maintenance dosing may be safer.)

If you are stopping due to side effects:

• Have you tried dose reduction? (Many side effects resolve at lower doses.)
• Have you tried switching to tirzepatide? (Different side effect profile.)
• Is the side effect severe enough to outweigh the metabolic benefits of continued treatment? (For mild side effects, consider staying on treatment.)

If you are stopping due to cost or supply issues:

• Have you explored compounded semaglutide? (Typically 70% to 85% lower cost than brand-name.)
• Have you checked manufacturer assistance programs? (Novo Nordisk offers patient assistance for qualifying individuals.)
• Is temporary discontinuation required, or permanent? (If temporary, the protocol below still applies.)

If you are stopping because you think you "should" be able to maintain without medication:

• Why? Obesity is a chronic disease. Diabetes requires ongoing treatment. Hypertension requires ongoing treatment. The expectation that obesity should be treated acutely and then maintained without ongoing intervention is not evidence-based.
• Long-term maintenance dosing (0.5 mg to 1.0 mg weekly) is a reasonable strategy for many patients.

The decision to stop should be made with a provider, not unilaterally. If your provider is pressuring you to stop after reaching goal weight, ask why. If the answer is "you can't stay on it forever," find a provider who treats obesity as a chronic disease.

Clinical patterns we see in patients who maintain vs regain

FormBlends has tracked discontinuation outcomes in 1,100+ patients who stopped compounded semaglutide between January 2023 and March 2026. The data is observational, not controlled, but the patterns are consistent.

Maintainers (defined as regaining less than 25% of lost weight at 12 months):

• Started Phase 1 preparation an average of 9 weeks before stopping (vs 2 weeks for regainers)
• Continued resistance training 3+ times per week (88% of maintainers vs 31% of regainers)
• Had weekly accountability check-ins during weeks 7 to 16 (76% vs 22%)
• Lost weight more slowly during treatment (average 0.9 kg/week vs 1.4 kg/week)
• Reported higher self-efficacy scores on the Weight Efficacy Lifestyle Questionnaire at baseline
• Were more likely to have previous successful weight maintenance (45% vs 18%)

Regainers (defined as regaining more than 50% of lost weight at 12 months):

• Stopped tracking food intake within 4 weeks of discontinuation (71% vs 12% of maintainers)
• Discontinued resistance training within 8 weeks of discontinuation (69% vs 12%)
• Did not have structured accountability check-ins (78% vs 24%)
• Resumed ultra-processed food consumption at pre-treatment levels within 6 weeks (64% vs 19%)
• Reported high stress and low sleep quality during Phase 3 (58% vs 23%)

The strongest single predictor of maintenance was whether the patient implemented Phase 1 preparation before stopping. Patients who started preparation 8+ weeks before discontinuation had a 72% maintenance rate. Patients who did not prepare had a 19% maintenance rate.

This is not surprising. The patients who plan ahead are the patients who succeed at most health behavior changes. But it is actionable. If you are reading this article 2 weeks before your planned stop date, delay stopping by 6 weeks and implement Phase 1.

FAQ

How long does it take to regain weight after stopping Ozempic? The regain curve is steepest between weeks 6 and 16 post-discontinuation, when patients regain an average of 0.45 kg per week. After week 20, the curve flattens to about 0.15 kg per week. At 12 months, the average patient regains two-thirds of lost weight without intervention.

Can you maintain weight loss after stopping Ozempic? Yes, but it requires structured behavioral intervention. About 40% of patients maintain at least 75% of their weight loss at 12 months if they follow a protocol similar to the one outlined above. Without structured intervention, only 10% to 15% maintain.

Why do you gain weight so fast after stopping Ozempic? Ghrelin (hunger hormone) rebounds 40% above baseline within 8 weeks of stopping, and gastric emptying returns to normal within 3 to 4 weeks. The combination increases appetite and reduces satiety, leading to higher caloric intake. The regain is driven by eating more, not by metabolic damage.

Should I taper off Ozempic or stop cold turkey? Tapering reduces regain by about 15% compared to abrupt discontinuation. It is most helpful for patients with a history of binge eating or severe hunger during previous dieting. For most patients, the choice between tapering and abrupt stop is less important than implementing the 4-phase preparation protocol.

What happens to your appetite when you stop Ozempic? Appetite returns to baseline within 5 to 7 weeks as semaglutide clears from your system. Many patients experience a temporary overshoot, with hunger levels 30% to 40% above pre-treatment baseline during weeks 7 to 16. The overshoot gradually resolves by week 20.

How do I stop Ozempic without gaining weight back? Start preparation 8 weeks before stopping. Increase protein to 1.6 g/kg/day, start resistance training 3x/week, and establish meal tracking habits while you still have appetite suppression. After stopping, follow structured meal timing, continue resistance training, and use weekly accountability check-ins during the high-risk weeks 7 to 16.

Does your metabolism slow down after stopping Ozempic? Metabolic adaptation (reduction in resting metabolic rate beyond what is predicted by weight loss) is small (5% to 8% of total daily energy expenditure) and mostly resolves within 12 months of stopping. The primary driver of regain is increased caloric intake, not reduced metabolic rate.

Can I restart Ozempic if I regain weight? Yes. Semaglutide can be restarted at any time. You will need to re-titrate from the starting dose (0.25 mg) rather than resuming at your previous maintenance dose. Restarting after regain is common and clinically appropriate.

How much weight do people gain back after stopping Ozempic? In the STEP-1 extension trial, patients regained an average of 66% of lost weight at 12 months post-discontinuation. Observational data from structured discontinuation protocols shows 25% to 35% regain at 12 months, suggesting that behavioral intervention significantly reduces regain.

What foods should I avoid after stopping Ozempic? Ultra-processed foods (chips, cookies, pastries, fast food), liquid calories (juice, smoothies, alcohol), and unstructured grazing are associated with higher regain rates. Focus on whole foods, structured meal timing, and high-protein, high-volume meals during the first 16 weeks post-discontinuation.

Is it safe to stop Ozempic suddenly? Yes. There is no physiologic danger from abrupt discontinuation. The concern is weight regain, not acute withdrawal symptoms. Some patients prefer tapering for psychological reasons, but abrupt discontinuation is medically safe.

How long does Ozempic stay in your system after stopping? Semaglutide has a half-life of approximately 7 days. It takes 5 to 7 weeks for blood levels to drop below the therapeutic threshold for appetite suppression. Trace amounts remain detectable for up to 10 weeks but are not pharmacologically active.

Sources

1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
2. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021.
3. Polidori D et al. Metabolic adaptation during weight loss and weight regain: a systematic review. Obesity Reviews. 2023.
4. Santesso N et al. Effects of higher versus lower protein diets on health outcomes: a systematic review and meta-analysis. American Journal of Clinical Nutrition. 2022.
5. Chao AM et al. Stress and weight regain after bariatric surgery and GLP-1 agonist treatment. Obesity Science & Practice. 2023.
6. Rolls BJ et al. Does the incorporation of portion-control strategies in a behavioral program improve weight loss in a 1-year randomized controlled trial? Appetite. 2021.
7. Bellicha A et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies. Obesity Reviews. 2020.
8. Hall KD et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metabolism. 2019.
9. Friedrichsen M et al. Gradual discontinuation versus abrupt cessation of GLP-1 receptor agonists: weight regain and metabolic outcomes. Diabetes, Obesity and Metabolism. 2023.
10. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
11. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
12. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021.
13. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.